Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Release

Printer Friendly Version View printer-friendly version
<< Back
Spring Bank Advances IV SB 11285 Clinical Program

-    Safety Review Committee for IV SB 11285 Phase 1a/1b trial recommends dose escalation to next planned monotherapy dose level and initiation of first co-administration dose level with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®)

-    Clinical Poster for IV SB 11285 Phase 1a/1b trial presented at the American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

HOPKINTON, Mass., June 03, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced that its Phase 1a/1b clinical trial of the company’s intravenously (IV)-administered STING agonist, SB 11285, continues to advance to an escalated monotherapy dosing level and the first cohort in which patients in the trial will receive the co-administration of the IV STING agonist and a checkpoint inhibitor. This Phase 1a/1b trial has been able to progress on track even in the midst of challenges posed by the COVID-19 pandemic.

SB 11285 is currently being evaluated as an IV-administered monotherapy in a Phase 1a/1b multicenter, dose escalation clinical trial in patients with advanced solid tumors. The Safety Review Committee for this clinical trial has recommended dose escalation to monotherapy dose level 3 and concurrent opening and dosing of combination dose level 1 with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®). To date, no dose limiting toxicities (DLTs) or drug-related serious adverse events (SAEs) have been observed.

“We are excited the Safety Review Committee for our IV SB 11285 Phase 1a/1b trial has recommended dose escalation to the next planned monotherapy dose level 3 and opening of concurrent combination dose level 1 with Roche’s PD-L1 checkpoint inhibitor Tecentriq,” said Atif Abbas, M.D., Vice President, Immuno-Oncology Clinical Development at Spring Bank. Dr. Abbas continued, “We are quite appreciative of the efforts displayed by one of our principal investigators to continue the conduct of our trial despite challenges presented by the COVID-19 pandemic. Also, we are thankful to Dr. Filip Janku of the MD Anderson Cancer Center for his insightful description of our ongoing Phase 1a/1b trial at the recently-concluded ASCO meeting.”

Dr. Filip Janku, Associate Professor at MD Anderson Cancer Center, presented a “trial in progress” poster (#226) at the ASCO Virtual Annual Meeting. This poster, which is available on the Publications page of Spring Bank’s website, outlines the IV SB 11285 STING agonist mechanism of action, SB 11285 in vivo data and trial design for the Phase 1a/1b ongoing trial.

About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleotide platform. The company designs its compounds to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its STING product portfolio with its lead clinical product candidate, SB 11285, an intravenously-administered immunotherapeutic agent for the treatment of selected cancers, its STING antagonist compounds for the treatment of a broad range of inflammatory diseases and its STING agonist ADC program for potential oncology applications. For more information, please visit www.springbankpharm.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended, about Spring Bank’s future expectations, plans and prospects. These statements include, but are not limited to, statements about the company’s Phase 1a/1b clinical trial for SB 11285 and the continued dosing of patients in, and the timing of availability of data from, this trial. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “will,” “would,” “could,” “potential,” “possible,” “hope,” “likelihood” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to: Spring Bank’s ability to successfully demonstrate the safety and efficacy of its product candidates; any delay of any current or planned non-clinical or clinical trials or the development of any product candidate, including any delays relating to clinical sites stopping enrolling and/or dosing patients; whether clinical sites determine to stop enrolling and/or dosing patients as a result of the impact of the COVID-19 pandemic; the impact of the COVID-19 pandemic on development programs and anticipated timelines; whether Spring Bank’s product candidates will advance through the clinical trial process on a timely basis, or at all; whether Spring Bank’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; whether the results of such trials will warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether Spring Bank’s product candidates will receive approval from regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully distributed and marketed; and other factors discussed in the “Risk Factors” section of Spring Bank’s Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the Securities and Exchange Commission (SEC) on February 14, 2020, and in other filings Spring Bank makes with the SEC from time to time.

In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof. Spring Bank anticipates that subsequent events and developments will cause Spring Bank’s views to change. However, while Spring Bank may elect to update these forward-looking statements at some point in the future, Spring Bank specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spring Bank’s views as of any date after the date hereof.

Investors:
LifeSci Advisors, LLC
Ashley R. Robinson
(617) 535-7742
Ashley@lifesciadvisors.com

Media:
McNeil, Gray & Rice
Kristin Nugent
Senior Account Supervisor
(617) 367-0100

Source: Spring Bank Pharmaceuticals, Inc.


Spring Bank logo.png

Source: Spring Bank Pharmaceuticals, Inc.